To Book an Appointment

Anti-Obesity Drugs: Benefits, Role, and Safety Concerns in MASLD Management

By Dr. Pallavi Garg in Gastroenterology, Hepatology & Endoscopy

Jan 06 , 2026 | 1 min read

Metabolic dysfunction-associated steatotic liver disease (MASLD), which was formerly called non-alcoholic fatty liver disease (NAFLD), is now a rising health concern closely related to type 2 diabetes, insulin resistance, and obesity. Global obesity rates are rising, and this increase is driving more cases of MASLD. Therefore, people must manage their weight with care.

Emergence of Anti-Obesity Medications

Recent advancements in anti-obesity medications offer new hope. Drugs like semaglutide and tirzepatide, originally developed for diabetes, are showing powerful weight-loss effects. These drugs mimic gut hormones like GLP-1 (glucagon-like peptide-1), which regulate appetite, glucose metabolism, and satiety. Tirzepatide, in particular, also targets GIP (glucose-dependent insulinotropic polypeptide), offering dual hormonal action for enhanced results.

Clinical Benefits in Weight and Liver Health

Clinical trials have demonstrated that with these medications patients are able to lose up to 15–20% of their body weight. Greatly reducing this weight improves insulin sensitivity and also reduces liver fat, key drivers of MASLD progression. Early data suggests that GLP-1 receptor agonists reduce hepatic steatosis and may improve liver inflammation and fibrosis, hallmarks of more severe MASLD.

The Role of Lifestyle and Need for Medication

Diet and exercise remain foundational. Pharmacologic support offers a workable solution for people struggling to achieve meaningful weight loss through lifestyle changes alone. Unfortunately, these drugs are easily available and are often used for cosmetic purposes without regard to medical limitations.

Limitations and Safety Concerns

To name a few limitations: cost, long-term safety, and access remain barriers. GI disturbances like bloating, fullness, diarrhoea, gallstones, and even pancreatitis have been reported. Long-term safety is still under research. Rebound weight gain after discontinuing these drugs is a well-documented concern. Additionally, they are currently approved for obesity and type 2 diabetes, not specifically for MASLD, though trials are showing promising results.

Conclusion

New anti-obesity drugs may be helpful in the fight against MASLD. As evidence grows, they may become part of a multidisciplinary approach that combines lifestyle, pharmacotherapy, and metabolic monitoring for comprehensive care. To date, lifestyle modification including dietary changes and regular exercise remains the cornerstone of MASLD management.

Written and Verified by: